YES
CAR T is here
//innovative therapy1

The first CAR T therapy for certain types of relapsed or refractory large B-cell lymphoma.

YES Manufacturing Matters
//Rapid and Reliable Manufacturing

In the ZUMA-1 (study design) pivotal trial, Kite demonstrated a median turnaround time of 17 days and 99% manufacturing success rate.1